IBIO iBio, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1420720 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY115.0%
TTM net income YoY-73.4%
TTM EPS YoY81.4%
Revenue 3-yr CAGR178.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-3,491.0%
Net margin-3,244.2%
FCF margin-2,566.3%
EBITDA margin-3,437.0%
Returns
ROE-51.8%
ROA-45.6%
ROIC (approx.)-97.5%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets11.4%
Debt / equity0.00x
Current ratio9.48x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.77x
Accruals ratio-10.4%
Payout ratio—
Capex / revenue60.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-06-30 | FY20252025-06-30 | FY20242024-06-30 | FY20232023-06-30 | FY20222022-06-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $100,000 | $400,000 | $225,000 | $0 | $1.88M |
| Cost of revenue | — | — | — | — | $216,000 |
| Gross profit | — | — | — | — | $2.17M |
| R&D expense | $19.64M | $8.31M | $5.18M | $10.33M | $9.83M |
| SG&A expense | $10.60M | $10.69M | $11.67M | $19.02M | $21.75M |
| Operating income | -$35.14M | -$18.60M | -$16.63M | -$29.34M | -$29.70M |
| Interest expense | $53,000 | $212,000 | $172,000 | $83,000 | $1.41M |
| Pretax income | -$33.04M | -$18.38M | — | — | — |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$33.04M | -$18.38M | -$24.91M | -$65.01M | -$50.30M |
| EBITDA | -$34.58M | -$18.12M | -$16.00M | -$28.67M | -$27.42M |
| EPS (basic) | -0.32 | -1.75 | -6.50 | -106.19 | -5.78 |
| EPS (diluted) | -0.32 | -1.75 | -6.50 | -106.19 | -5.78 |
| Weighted avg. shares (diluted) | 104.06M | 10.50M | 3.83M | 612,000 | 8.72M |
| Balance sheet | |||||
| Cash & equivalents | $56.40M | $8.79M | $14.43M | $7.58M | $28.67M |
| Short-term investments | $31.64M | $0 | $0 | — | — |
| Receivables | — | $0 | $0 | $0 | $1.00M |
| Inventory | — | — | $0 | $0 | $3.90M |
| Current assets | $92.22M | $9.72M | $15.67M | $26.26M | $45.07M |
| PP&E, net | $3.09M | $3.16M | $3.63M | $4.22M | $1.37M |
| Intangibles | $1.82M | $6.85M | $5.37M | $5.39M | $4.85M |
| Total assets | $99.11M | $23.18M | $28.73M | $41.21M | $99.41M |
| Current liabilities | $11.74M | $6.11M | $3.84M | $22.11M | $30.44M |
| Total liabilities | $13.40M | $8.30M | $7.41M | $25.83M | $35.92M |
| Shareholders' equity | $85.71M | $14.88M | $21.32M | $15.38M | $63.48M |
| Shares outstanding | 55.70M | 19.35M | 8.62M | 1.02M | 8.73M |
| Cash flow statement | |||||
| Operating cash flow | -$23.22M | -$15.30M | -$18.55M | -$30.44M | -$37.48M |
| Capital expenditure | $578,000 | $16,000 | $210,000 | $5.74M | $7.33M |
| Free cash flow | -$23.80M | -$15.32M | -$18.76M | -$36.17M | -$44.81M |
| Investing cash flow | -$32.00M | $742,000 | $906,000 | $7.01M | -$5.13M |
| Financing cash flow | $103.05M | $8.93M | $24.49M | $2.30M | -$6.12M |
| Depreciation & amortization | $558,000 | $484,000 | $638,000 | $674,000 | $2.27M |
| Stock-based compensation | $1.37M | $1.53M | $2.04M | $4.39M | $4.38M |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.